The Swiss Stock Exchange starts in the red
The Swiss Stock Exchange started the session in the red this Wednesday morning, after having lost ground the day before. Market observers were preparing to analyze the PMI indexes of services in the euro zone and the United States expected today, after the publication of that of China, behind.
“European clues should open this morning in the wake of the results considered to be mediocre alphabet, Google’s parent company after the turnover of its activity” Cloud “was lower than forecasts, while its investments In artificial intelligence weighed on the cash flow, provided for John Plassard in his daily stock market commentary.
He pointed out that questions concerning the potential American customs tariffs against Europe continued to weigh on the morale of investors.
In China, the activity index of purchasing directors (PMI) for services, calculated by S&P Global and the Chinese economic media Caixin, fell to 51 points in January, against 52.2 the previous month.
Investors also awaited the PMI index of euro zone services, the publication of which was scheduled for 11 a.m., and that of the United States announced for 5 p.m.
Around 9:10 am on the Swiss Stock Exchange, the Swiss Market Index (SMI) ceded 0.18% to 12,453.58 points, the Swiss Leader Index (SLI) 0.24% to 2044.81% and the Swiss Performance Index (SPI) 0 , 18% to 16,525.44 points. Out of the thirty stars, only seven stayed afloat.
Among the heavy goods vehicles, Novartis and the Bon Roche was doing well, winning 0.6%and 0.1%respectively, on the first and last step of the podium, while Nestlé was shed 0.3%. Straumann, with a gain of 0.3% was in second position.
At the back of the peloton, we spotted UBS (-1.4%), the Swatch group (-1.3%) and Lindt (-0.7%).
On the enlarged market, Dormakaba took 3.5% after having announced to expect a significant increase in its net profit in the first half of its 2024/25 fiscal year, closed in late December. The sale of a site in Montreal partly explains this unexpected news, according to the specialist in doors and locks.
The Bernese banking group Valiant also was 3.5%. He recorded net profit increased by 4.2% to 150.4 million francs during his financial year 2024.
Basilea scored 0.3%. The pharmaceutical company has seen the sales of its antimycosics Cresemba (Isavuconazole) cross a first predefined commercial milestone in Japan, triggering a step payment equivalent to 1.2 million francs from its local distribution partner Asahi Kasei Pharma ( AKP). (Awp)